600216 浙江医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.5888.09011.4464.5495.982
总资产报酬率 ROA (%)2.0316.2648.7343.4084.323
投入资产回报率 ROIC (%)2.3587.42410.5234.1605.411

边际利润分析
销售毛利率 (%)35.05534.66842.33232.38734.470
营业利润率 (%)13.98310.84313.0464.8776.218
息税前利润/营业总收入 (%)15.6929.89512.8784.4375.587
净利润/营业总收入 (%)11.7938.56110.8823.5514.468

收益指标分析
经营活动净收益/利润总额(%)91.850111.732118.88330.963128.977
价值变动净收益/利润总额(%)3.4420.759-2.442-3.745-11.500
营业外收支净额/利润总额(%)0.032-1.177-0.893-4.646-2.692

偿债能力分析
流动比率 (X)3.3882.9562.5632.2602.294
速动比率 (X)2.5372.1961.7331.4491.485
资产负债率 (%)19.84321.30221.22121.85621.900
带息债务/全部投入资本 (%)7.5326.8666.2657.4438.284
股东权益/带息债务 (%)1,206.5121,331.5791,470.2851,232.7411,100.412
股东权益/负债合计 (%)399.541364.582363.724344.798340.092
利息保障倍数 (X)9.209-12.042-243.513-19.773-11.943

营运能力分析
应收账款周转天数 (天)62.83862.72955.28558.89560.809
存货周转天数 (天)115.485123.701137.940136.804130.911